InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,745.37
(
0.40%
)
US TECH 100
19,572.00
(
0.72%
)
Dow Jones
42,175.11
(
0.62%
)
Brent Oil
70.72
(
-0.33%
)
Bitcoin
65,070.39
(
-0.17%
)
Post# of 253241
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120506
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech jim post# 215096

Monday, 11/13/2017 6:58:36 PM

Monday, November 13, 2017 6:58:36 PM

Post# of 253241

Has NVS provided any update on the manufacturing issue they have with brolucizumab [RTH258]?

The BLA is delayed until NVS can complete a bridging study to show that the two formulations are equivalent.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up